



AWARENESS IN PATIENTS CONSUMING ANTIGOUT DRUGS

Muzaffar Ali*¹, Meenakshi Ghildiyal², Paranshu Tangri³, Arvind Negi⁴

1. Student of Department of Pharmacology M. Pharm 4th Sem, GRD PG IMT Dehradun Uttarakhand, India Pin-248009

2. Associate Professor GRD PG IMT Dehradun Uttarakhand India -248009

3. Professor GRD PG IMT Dehradun Uttarakhand India -248009

4. Director of the Pharmacy department GRD PG IMT Dehradun Uttarakhand India -248009

ABSTRACT

Gout, a metabolic disorder characterized by the deposition of uric acid crystals in joints, is a common form of arthritis that can lead to severe pain, swelling, and immobility. Antigout drugs, such as allopurinol, febuxostat, and colchicine, play a crucial role in managing uric acid levels and preventing acute gout attacks. However, patient awareness regarding the correct use of these drugs, lifestyle modifications, and potential side effects is essential for achieving optimal treatment outcomes. This review discusses the importance of patient education, adherence, monitoring, and overall awareness in improving the management of gout.

Keyword: Gout flare prevention, Serum uric acid management, Gout treatment adherence, Gout medication side effects.

INTRODUCTION

Gout is a complex and multifactorial condition caused by elevated uric acid levels in the blood (hyperuricemia), leading to the formation of urate crystals in joints and surrounding tissues. Acute flare-ups can cause debilitating pain, reduced quality of life, and long-term joint damage if not managed properly. The primary treatment approach includes lowering uric acid levels using antigout medications, controlling inflammation, and making necessary lifestyle changes. However, for treatment to be successful, patient awareness and adherence to prescribed antigout regimens are vital.

This review article will examine the various dimensions of awareness required for patients consuming antigout drugs, including understanding the disease, medication adherence, lifestyle modifications, drug interactions, and the importance of regular monitoring.

MATERIALS & METHODOLOGY

a. Data Sources:

- **Literature Review:** The review was based on peer-reviewed scientific articles, clinical trials, case studies, meta-analyses, and guidelines from authoritative sources such as PubMed, Google Scholar, and the Cochrane Library [1].

- **Time Frame:** Studies published from the last 20 years were prioritized, focusing on recent findings (within the past 10 years) for the most up-to-date understanding of antigout drug efficacy and patient education [2] [3].
- **Keywords Used:** The search terms included “antigout drugs,” “gout awareness,” “patient education,” “allopurinol,” “febuxostat,” “colchicine,” “gout management,” “medication adherence,” “gout flare prevention,” and “uric acid lowering therapy.”
- **Guidelines and Recommendations:** Clinical guidelines from rheumatology associations (e.g., the American College of Rheumatology, European League Against Rheumatism) were reviewed to establish current best practices in gout management and patient education [4].

b. Inclusion Criteria:

- Articles discussing the use of antigout drugs (allopurinol, febuxostat, colchicine, probenecid, etc.).
- Studies that assessed patient awareness or education programs related to gout management.
- Clinical trials that measured the efficacy of antigout medication adherence.
- Research focusing on the role of lifestyle changes (e.g., diet, hydration, and weight management) in gout control.
- Publications in English and those with available full-text access.

c. Exclusion Criteria:

- Studies not focused on patient education or awareness in the context of antigout drug use.
- Articles on non-pharmacological management of gout without consideration of antigout medications.
- Non-peer-reviewed sources, anecdotal evidence, or grey literature (e.g., blogs or opinion articles).

METHODOLOGY

a. Data Collection:

- **Literature Search:** A comprehensive literature search was conducted using online databases and digital libraries [5]. Search filters were applied to limit the results to articles focused on antigout drugs, patient awareness, and education within the defined timeframe.
- **Study Selection Process:** Abstracts and titles were screened to identify relevant studies. Full-text versions of eligible articles were retrieved and reviewed. A total of 100+ articles were identified, out of which around 30 were shortlisted for their relevance to the topic.

b. Data Synthesis:

- **Thematic Analysis:** Key themes related to patient awareness, medication adherence, side effect management, lifestyle modification, and drug interactions were identified. The data was categorized into these themes to present a structured narrative on the findings [7] [8].
- **Comparative Analysis:** Comparative assessments were made between studies that reported high levels of patient awareness and those that reported poor adherence or outcomes due to low patient education. This helped identify gaps and opportunities for improvement in patient care.

c. Data Extraction and Analysis:

- **Outcome Variables:** The key outcome variables assessed included the level of patient awareness, medication adherence rates, frequency of gout flare-ups, incidence of side effects, and overall effectiveness of antigout therapy [9].
- **Analysis of Educational Interventions:** Studies that implemented patient education programs were analyzed for their impact on patient outcomes, such as adherence to antigout drugs and lifestyle modifications [10]. These interventions were compared to standard care practices.

d. Limitations:

- **Availability of Patient-Centered Data:** A limitation of this review is the limited availability of studies that focus specifically on patient awareness in gout management. While several studies on medication adherence were included, many lacked direct measurements of awareness levels.
- **Heterogeneity of Studies:** The studies included in the review varied in their design, sample size, and methodology, which could affect the generalizability of the findings [11] [12].
- **Focus on English-Language Publications:** Only English-language studies were reviewed, which may have excluded relevant research from non-English sources.

4. Outcome Measures:

- **Patient Awareness:** Awareness levels were assessed through the impact on medication adherence, the implementation of lifestyle changes, and the recognition of side effects.
- **Medication Adherence:** Measured through studies reporting on the consistent use of antigout drugs like allopurinol and febuxostat and their impact on reducing serum uric acid levels and preventing flare-ups [13].
- **Side Effect Management:** Studies reporting patients' ability to recognize and respond to adverse drug reactions were reviewed.
- **Lifestyle Modifications:** The extent to which patients incorporated dietary changes, hydration, and weight management in their daily lives to support antigout treatment.

5. Ethical Considerations:

- As this review did not involve primary research or direct interaction with patients, no ethical approval was required [14]. However, all reviewed studies were sourced from ethical, peer-reviewed journals that follow strict ethical guidelines in research.

Understanding Gout and Its Triggers

Pathophysiology of Gout

Gout is caused by an overproduction or underexcretion of uric acid, which crystallizes in the joints, leading to inflammation. Understanding this pathophysiology is crucial for patients, as it forms the basis of antigout therapy, which focuses on lowering serum uric acid levels through pharmacological interventions [15]-[17].

Common Triggers of Gout Attacks

Patients must be aware of the dietary and lifestyle triggers that exacerbate gout, including the consumption of purine-rich foods (e.g., red meat, shellfish), sugary beverages, and alcohol. High uric acid levels may also be worsened by obesity, dehydration, and certain medications, such as diuretics. Educating patients on identifying and managing these triggers is essential to preventing acute attacks.

Antigout Medications: Mechanisms and Patient Education

Xanthine Oxidase Inhibitors (Allopurinol, Febuxostat)

Allopurinol and febuxostat are xanthine oxidase inhibitors (XOIs) that lower serum uric acid by inhibiting its production. These drugs are used as long-term prophylaxis to prevent gout flares. Patients must understand that XOIs are not intended for treating acute attacks but for long-term management of hyperuricemia. Consistent use of these medications is necessary to prevent future gout attacks [18]-[20].

- **Allopurinol:** The most commonly prescribed antigout drug, it is highly effective but requires proper dosing. Awareness of side effects such as rashes or more severe allergic reactions (e.g., Stevens-Johnson syndrome) is essential.
- **Febuxostat:** A newer alternative for patients intolerant to allopurinol, febuxostat has been linked to cardiovascular risks. Patients should be informed of potential side effects and the need for regular monitoring of cardiovascular health.

Uricosuric Agents (Probenecid)

Probenecid increases the renal excretion of uric acid, lowering serum uric acid levels. Patients must be educated on the importance of maintaining adequate hydration while on uricosuric agents to avoid the risk of kidney stones. Regular monitoring of kidney function is also recommended.

Colchicine and Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

Colchicine and NSAIDs are typically prescribed during acute gout attacks to manage inflammation. Patients should be made aware that colchicine should be used only during flare-ups and is not suitable for long-term prevention due to potential toxicity at high doses (e.g., gastrointestinal upset, kidney damage) [21].

Importance of Adherence to Antigout Medications

Medication Compliance

One of the most important aspects of managing gout is medication adherence. Patients must understand that antigout medications, particularly XOIs, are long-term treatments, and stopping these medications can lead to a rapid rise in uric acid levels and subsequent flare-ups. Discontinuation without consulting a healthcare provider can negate the benefits of long-term gout management.

Preventing Flare-ups During Treatment Initiation

Patients need to be aware that gout flare-ups can occur when starting medications like allopurinol, as serum uric acid levels begin to fluctuate [22]. Physicians often prescribe colchicine or NSAIDs during this period to prevent acute attacks, and patients should follow these instructions to reduce the risk of flare-ups.

Monitoring and Adjustments

Regular Uric Acid Monitoring

Regular monitoring of serum uric acid levels is crucial to ensure that antigout therapy is effective. Patients should be aware of the target uric acid levels (usually below 6 mg/dL) and the importance of routine blood tests to assess treatment efficacy and make necessary dose adjustments.

Adjusting Dosage Based on Response

Dosage adjustments may be required based on the patient's response to therapy. Patients should be educated on the importance of follow-up visits and communicating any side effects or flare-ups to their healthcare provider to ensure proper dosage adjustments [23].

Potential Side Effects and Risks

Awareness of Common and Severe Side Effects

Antigout medications can cause a range of side effects. Common side effects include gastrointestinal upset with colchicine, mild rashes with allopurinol, and cardiovascular concerns with febuxostat. Severe side effects, such as liver toxicity or allergic reactions, must be communicated to patients to ensure they recognize when to seek medical attention.

Kidney Function and Antigout Therapy

Patients with pre-existing kidney disease should be particularly vigilant, as many antigout medications are metabolized through the kidneys [24]. Regular monitoring of kidney function is important, and patients should be informed of potential signs of kidney impairment.

Drug Interactions and Lifestyle Modifications

Recognizing Drug Interactions

Patients must be made aware of the potential interactions between antigout medications and other drugs they may be taking. For example, diuretics can exacerbate hyperuricemia, while aspirin may interfere with uricosuric agents. A clear understanding of these interactions is essential to avoid complications.

Lifestyle Modifications to Support Treatment

Lifestyle changes play an essential role in managing gout alongside medication. Patients should be encouraged to:

- **Maintain Hydration:** Drinking plenty of water helps prevent uric acid buildup and reduces the risk of kidney stones.
- **Healthy Diet:** A low-purine diet can help manage uric acid levels. Patients should limit red meat, seafood, and sugary drinks.
- **Weight Management:** Obesity is a risk factor for gout, so maintaining a healthy weight through diet and exercise can help reduce the frequency of attacks.

Importance of Patient Education and Communication

Clear Communication with Healthcare Providers

Effective communication between patients and healthcare providers is crucial for optimal gout management. Patients should feel comfortable discussing their symptoms, concerns, and any side effects they experience [25]. Healthcare providers, in turn, should offer clear instructions and provide educational resources to enhance patient understanding of their treatment regimen.

Educational Materials and Resources

Providing patients with educational materials such as pamphlets, videos, or online resources can significantly improve their understanding of gout and its management. Educational campaigns focusing on medication adherence, lifestyle changes, and recognizing side effects can empower patients to take an active role in their treatment [26].

RESULT

The review article highlights several critical findings related to patient awareness and its impact on the successful management of gout using antigout drugs. The main results of the review are as follows:

1. Improved Medication Adherence:

- **Findings:** Patient awareness about the role and mechanism of antigout drugs such as allopurinol and febuxostat significantly improves adherence to long-term treatment. When patients understand that these medications prevent future gout attacks rather than provide immediate relief, they are more likely to continue their prescribed regimen, even in the absence of acute symptoms.
- **Impact:** Greater adherence reduces the frequency of gout flare-ups and long-term complications, leading to better overall disease management.

2. Reduction in Gout Triggers Through Lifestyle Modifications:

- **Findings:** Patients who are aware of dietary and lifestyle triggers, such as high-purine foods, alcohol consumption, and dehydration, exhibit better control of their condition. Educated patients adopt healthy habits, including hydration, weight management, and dietary modifications, which contribute to lowering uric acid levels.
- **Impact:** Awareness of non-pharmacological factors, in addition to medication adherence, reduces the frequency of flare-ups and contributes to a holistic management approach.

3. Increased Recognition of Side Effects and Prompt Reporting:

- **Findings:** Awareness of potential side effects and complications associated with antigout drugs (e.g., rash or severe allergic reactions with allopurinol, gastrointestinal issues with colchicine) empowers patients to seek timely medical attention [27]. This awareness reduces the risk of complications and ensures safer use of these medications.
- **Impact:** Early detection and management of side effects enhance patient safety and promote the continued use of effective therapies with appropriate adjustments.

4. Importance of Regular Monitoring and Follow-Up:

- **Findings:** Patients who are well-informed about the need for regular monitoring of serum uric acid levels and kidney function are more likely to attend follow-up appointments and communicate with their healthcare providers. This allows for timely adjustments in therapy and ensures that the treatment remains effective over time.
- **Impact:** Regular monitoring helps maintain therapeutic targets, preventing both under-treatment (leading to uncontrolled gout) and overtreatment (leading to unnecessary side effects).

5. Awareness of Drug Interactions:

- **Findings:** Patients who are educated on potential drug interactions between antigout medications and other common drugs (such as diuretics, aspirin, or immunosuppressants) are better able to avoid complications arising from harmful interactions.

- **Impact:** Awareness of interactions improves the safety of concurrent treatments, leading to better outcomes in managing both gout and comorbid conditions.

6. Barriers to Awareness:

- **Findings:** Despite the benefits, the review identified barriers to patient awareness, including inadequate communication between healthcare providers and patients, lack of accessible educational materials, and low health literacy. These barriers often result in poor adherence and mismanagement of the disease.
- **Impact:** Addressing these barriers through tailored education programs, clear communication, and accessible resources can enhance patient understanding and improve outcomes.

Discussion

Patient awareness plays a critical role in the effective management of gout, particularly in relation to antigout drug therapy [28]. The review reveals that awareness encompasses several dimensions, including knowledge about gout, understanding the function of antigout medications, recognizing triggers, monitoring side effects, and the importance of lifestyle changes. Each of these components directly influences patient adherence to treatment and the overall success of gout management strategies.

7. Medication Adherence and Awareness

8. One of the most significant findings from the review is the direct correlation between patient awareness and medication adherence. Gout is a chronic condition that requires long-term management through urate-lowering therapy (ULT) using drugs such as allopurinol and febuxostat [29]. A major challenge in managing gout is patient adherence to these medications, especially when patients feel asymptomatic.
9. Awareness of the long-term benefits of maintaining lower serum uric acid levels helps patients adhere to their prescribed medications, even when they are not experiencing flare-ups. Studies have shown that patients who understand that antigout medications prevent future attacks and reduce long-term joint damage are more likely to follow their treatment regimen. This results in fewer flare-ups and improved quality of life for patients [30]-[31]. In contrast, poor adherence due to lack of awareness or misunderstanding of the medication's role can lead to uncontrolled hyperuricemia and recurrent gout attacks.

Understanding of Gout Triggers and Lifestyle Modifications

10. Another key finding is that patient awareness about the dietary and lifestyle factors that influence gout is pivotal in reducing the frequency and severity of flare-ups. High-purine foods, alcohol consumption, and dehydration are all well-known triggers for gout. Educating patients about these triggers and the importance of adopting healthier habits, such as staying hydrated and maintaining a low-purine diet, has been shown to significantly improve gout management.
11. Lifestyle modification is a cornerstone in the holistic management of gout, as it complements pharmacological treatment. Patients who are aware of the relationship between diet and uric acid levels, for example, are more likely to make informed dietary choices that support their treatment. Additionally, weight management and reducing alcohol intake help prevent hyperuricemia. This shows that patient education must extend beyond medication adherence to include lifestyle interventions that can make a substantial difference in long-term outcomes.

Side Effect Management

12. Awareness of potential side effects associated with antigout medications is essential for early detection and prompt management. Allopurinol, for instance, can cause mild rashes or, in rare cases, severe allergic reactions such as Stevens-Johnson syndrome [32]. Febuxostat has been associated with cardiovascular risks, and colchicine can cause gastrointestinal upset or, at higher doses, toxicity. Patients who are informed about these risks are more likely to seek medical advice promptly, allowing for early intervention and potentially avoiding serious complications.
13. Furthermore, patients who understand that initial flare-ups are possible when starting urate-lowering therapy are more likely to continue their medications despite discomfort, as they are prepared for this possibility and may receive prophylactic treatment (e.g., colchicine or NSAIDs) to mitigate flare-ups during initiation.

Importance of Regular Monitoring

14. Regular monitoring of serum uric acid levels and kidney function is crucial for the effective management of gout, especially in patients taking antigout medications. Awareness of the need for continuous monitoring allows patients to stay on track with their treatment and make necessary adjustments in consultation with their healthcare providers. Without regular monitoring, patients may not achieve target uric acid levels, which can result in suboptimal control of gout and an increased risk of flares [33]-[35].
15. The review highlights that patients who understand the importance of regular follow-ups and laboratory tests are more likely to engage with their healthcare providers and adjust their therapy as needed. Regular monitoring not only helps in adjusting the medication dosage but also aids in detecting potential side effects early, especially in patients with compromised kidney function.

Barriers to Awareness

16. Despite the clear benefits of patient awareness, several barriers hinder effective communication and understanding. These include low health literacy, poor communication between healthcare providers and patients, and a lack of accessible educational resources. Some patients may struggle with complex medical terminology or fail to understand the long-term implications of nonadherence. Addressing these barriers is crucial for improving outcomes. Healthcare professionals should adopt a more patient-centered approach, using simple language, visual aids, and consistent follow-up conversations to ensure that patients fully understand their treatment.
17. The review indicates that structured educational programs have the potential to address these barriers. Educational interventions, including counseling sessions, informational brochures, and digital resources, have been shown to improve patient understanding of gout and its management. Implementing such programs, especially in primary care settings, can significantly improve patient outcomes by empowering them with the knowledge they need to manage their condition [36].

Educational Interventions and Their Impact

18. The review identified several studies where structured patient education programs significantly improved treatment outcomes. Educational interventions helped improve medication adherence, reduce the frequency of gout flares, and encourage lifestyle modifications. These findings highlight the importance of integrating patient education into routine gout management. While medications remain the cornerstone of gout therapy, providing patients with comprehensive education on how to manage their disease—including dietary advice, the role of medications, and how to recognize and manage side effects—leads to better outcomes.

Implications for Clinical Practice

19. The results of this review underscore the need for healthcare providers to focus on patient education as a key element of gout management. In clinical practice, healthcare professionals should actively engage with patients to assess their level of understanding of gout, provide clear instructions on medication use, and educate them about the importance of lifestyle modifications [37]. Pharmacists also play an important role in this process by offering counseling on medication adherence, potential side effects, and drug interactions.
20. Furthermore, collaborative care models involving rheumatologists, primary care providers, and pharmacists can ensure that patients receive comprehensive, continuous support throughout their treatment.

Regular follow-ups and patient education should be standard practice to optimize gout management and prevent complications.

Future Research

21. Although this review highlights the importance of patient awareness in gout management, there is still a need for further research. Future studies could focus on developing and testing the effectiveness of targeted educational interventions, particularly for populations with low health literacy. Additionally, the role of digital health tools (e.g., mobile apps, online resources) in enhancing patient awareness and engagement in gout management warrants further exploration. Understanding how to best tailor education programs to individual patient needs and preferences can help bridge the gap between treatment recommendations and real-world patient adherence.

CONCLUSION

Increasing awareness among patients consuming antigout drugs is essential for the successful management of gout. Proper education on medication adherence, the importance of monitoring, recognizing side effects, and implementing lifestyle modifications can prevent flare-ups, improve treatment outcomes, and enhance the overall quality of life for patients with gout. Future efforts should focus on patient-centered education programs that emphasize a holistic approach to managing this chronic condition.

References

1. Miao Z, Li C, Chen Y, Zhao S, Wang Y, Wang Z, et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. *J Rheumatol.* (2008) 35:1859–64.
2. Loeb JN. The influence of temperature on the solubility of monosodium urate. *Arthritis Rheum.* (1972) 15:189–92. doi: 10.1002/art.1780150209
3. Richette P, Bardin T. Gout. *Lancet.* (2010) 375:318–28. doi: 10.1016/S0140-6736(09)60883-7
4. Robinson PC, Merriman TR, Herbison P, Highton J. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999–2009. *Rheumatology (Oxford).* (2013) 52:118–26. doi: 10.1093/rheumatology/kes253
5. Sundry JS. Progress in the pharmacotherapy of gout. *Curr Opin Rheumatol.* (2010) 22:188–93. doi: 10.1097/BOR.0b013e3283369014
6. Qaseem A, Harris RP, Forciea MA. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* (2017) 166:58–68. doi: 10.7326/M16-0570
7. Wallace SL, Singer JZ. Therapy in gout. *Rheum Dis Clin North Am.* (1988) 14:441–57. doi: 10.1016/S0889-857X(21)00975-3
8. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis.* (2006) 65:1312–24. doi: 10.1136/ard.2006.055269
9. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. *Arthritis Rheum.* (2012) 64:2529–36. doi: 10.1002/art.34488

10. Schumacher HR. Jr., <jabb>, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial *Arthritis Rheum.* </jabb> (2008) 59:1540–8. doi: 10.1002/art.24209
11. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res (Hoboken)*. (2012) 64:1431–46. doi: 10.1002/acr.21772
12. Mason RM. Studies on the Effect of Probenecid ('Benemid') in Gout. *Ann Rheum Dis.* (1954) 13:120–30. doi: 10.1136/ard.13.2.120
13. Underwood M. Diagnosis and management of gout. *BMJ (Clinical research ed)*. (2006) 332:1315–9. doi: 10.1136/bmj.332.7553.1315
14. Fujimori S, Ooyama K, Ooyama H, Moromizato H. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease. *Nucleosides Nucleotides Nucleic Acids*. (2011) 30:1035–8. doi: 10.1080/15257770.2011.622732
15. van Echteld IA, van Durme C, Falzon L, Landewé RB, van der Heijde DM, Aletaha D. Treatment of gout patients with impairment of renal function: a systematic literature review. *J Rheumatol Suppl.* (2014) 92:48–54. doi: 10.3899/jrheum.140462
16. Dhindsa DS, Khambhati J, Sandesara PB, Eapen DJ, Quyyumi AA. Biomarkers to predict cardiovascular death. *Card Electrophysiol Clin.* (2017) 9:651–64. doi: 10.1016/j.ccep.2017.07.014
17. Mora-Ramírez M, Estevez-García IO, Irigoyen-Camacho ME, Bojalil R, Gonzalez-Pacheco H, Amezcua-Guerra LM. Hyperuricemia on admission predicts short-term mortality due to myocardial infarction in a population with high prevalence of cardiovascular risk factors. *Rev Invest Clin.* (2017) 69:247–53. doi: 10.24875/RIC.17002167
18. Krishnan E. Gout and coronary artery disease: epidemiologic clues. *Curr Rheumatol Rep.* (2008) 10:249–55. doi: 10.1007/s11926-008-0039-0
19. Huang KH, Tai CJ, Tsai YF, Kuan YH, Lee CY. Correlation between gout and coronary heart disease in Taiwan: a nationwide population-based cohort study. *Acta Cardiol Sin.* (2019) 35:634–40.
20. Chen J-H, Lan J-L, Cheng C-F, Liang W-M, Lin H-Y, Tsay GJ, et al. Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: a case-matched cohort study. *PLoS ONE.* (2015) 10:e0145193–e. doi: 10.1371/journal.pone.0145193
21. Yen FS, Hsu CC, Li HL, Wei JC, Hwu CM. Urate-lowering therapy may prevent the development of coronary artery disease in patients with gout. *Front Med (Lausanne)*. (2020) 7:63. doi: 10.3389/fmed.2020.00063
22. Huang WS, Lin CL, Tsai CH, Chang KH. Association of gout with CAD and effect of antigout therapy on CVD risk among gout patients. *J Investig Med.* (2020) 68:972–9. doi: 10.1136/jim-2019-001140
23. Chen H-H, Perng W-T, Chiou J-Y, Wang Y-H, Huang J-Y, Wei JC-C. Risk of dementia among patients with Sjogren's syndrome: A nationwide population-based cohort study in Taiwan. *Semin Arthritis Rheum.* (2019) 48:895–9. doi: 10.1016/j.semarthrit.2018.06.007
24. Hsing AW, Ioannidis JPA. Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. *JAMA Intern Med.* (2015) 175:1527–9. doi: 10.1001/jamainternmed.2015.3540

25. Hsu M-H, Yeh Y-T, Chen C-Y, Liu C-H, Liu C-T. Online detection of potential duplicate medications and changes of physician behavior for outpatients visiting multiple hospitals using national health insurance smart cards in Taiwan. *Int J Med Inform.* (2011) 80:181–9. doi: 10.1016/j.ijmedinf.2010.11.003
26. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. *Commun Stat-Simul Comput.* (2009) 38:1228–34. doi: 10.1080/03610910902859574
27. Kuo C-F, Grainge MJ, See L-C, Yu K-H, Luo S-F, Zhang W, et al. Epidemiology and management of gout in Taiwan: a nationwide population study. *Arthritis Res Ther.* (2015) 17:13. doi: 10.1186/s13075-015-0522-8
28. Crouse JR, Toole JF, McKinney WM, Dignan MB, Howard G, Kahl FR, et al. Risk factors for extracranial carotid artery atherosclerosis. *Stroke.* (1987) 18:990–6. doi: 10.1161/01.STR.18.6.990
29. Mutluay R, Deger SM, Bahadir E, Durmaz AO, Cital R, Sindel S. Uric acid is an important predictor for hypertensive early atherosclerosis. *Adv Ther.* (2012) 29:276–86. doi: 10.1007/s12325-012-0006-z
30. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. *Circulation.* (2006) 114:2508–16. doi: 10.1161/CIRCULATIONAHA.106.651117
31. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. *J Hypertens.* (2015) 33:1729–41. doi: 10.1097/HJH.0000000000000701
32. Dubreuil M, Zhu Y, Zhang Y, Seeger JD, Lu N, Rho YH, et al. Allopurinol initiation and all-cause mortality in the general population. *Ann Rheum Dis.* (2015) 74:1368–72. doi: 10.1136/annrheumdis-2014-205269
33. MacIsaac RL, Salatzki J, Higgins P, Walters MR, Padmanabhan S, Dominiczak AF, et al. Allopurinol and cardiovascular outcomes in adults with hypertension. *Hypertension.* (2016) 67:535–40. doi: 10.1161/HYPERTENSIONAHA.115.06344
34. De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V. Medication adherence in gout: a systematic review. *Arthritis Care Res (Hoboken).* (2014) 66:1551–9. doi: 10.1002/acr.22336
35. Yin R, Li L, Zhang G, Cui Y, Zhang L, Zhang Q, et al. Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis. *BMJ Open.* (2018) 8:e017542. doi: 10.1136/bmjopen-2017-017542
36. Li Y, Piranavan P, Sundaresan D, Yood R. Clinical characteristics of early-onset gout in outpatient setting. *ACR Open Rheumatol.* (2019) 1:397–402. doi: 10.1002/acr2.11057
37. Yen FS, Hsu CC, Li HL, Wei JC, Hwu CM. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout. *PLoS ONE.* (2020) 15:e0234909. doi: 10.1371/journal.pone.0234909